CEMO News December 2015

This is the December 2015 edition of NEW Devon CCG Medicines Optimisation News. Please note that the primary audience for this newsletter are GP practices and community pharmacies within NEW Devon and that the information may be specific to them and also to the North & East Formulary and South & West Formulary. This is produced by the Clinical Effectiveness and Medicines Optimisation team at NEW Devon CCG. Content of this newsletter is available on NEW Devon CCG intranet [here](#).

Contents of this newsletter: (click on hyperlink to go straight to that article)

**Medicines Optimisation news**
- Important information regarding the restrictions to the licensed indication, modification of posology and additional contraindications and warning for Nicorandil 10mg and 20mg tablets (Ikorel 10mg and 20mg).
- Non-Medical Prescribers-Starters and Leavers
- Updated Guidance Sheet-Continence Top Tips-North and East
- ScriptSwitch and Windows 7 and other software or hardware upgrades

**Formulary news**
- South and West Continence Chapter-Intermittent Catheter product change
- Temporary shortage of INSUMAN BASAL and INSUMAN COMB 25 insulin human OUT OF STOCK INFORMATION

**Medicines Optimisation Governance news**
- Drug safety update November 2015

**Medicines Optimisation news**

*Important information regarding the restrictions to the licensed indication, modification of posology and additional contraindications and warning for Nicorandil 10mg and 20mg tablets (Ikorel 10mg and 20mg).*

In accordance with the European Medicines Agency (EMA) and the Medicines and Healthcare products Regulatory Agency (MHRA) the following update has been provided.

Nicorandil is now indicated for treatment of stable angina only in patients whose angina is inadequately controlled with first line anti-angina therapies, or who have a contraindication or intolerance to first line anti-angina therapies.

Nicorandil can cause serious skin, mucosal and eye ulceration which may persist. If ulceration develops on any part of the body treatment with nicorandil should be stopped. If stopping treatment worsens angina symptoms, consult a cardiologist. Gastrointestinal ulcers may progress to perforation, haemorrhage, fistula or abscess. Patients taking aspirin, non-steroidal anti-inflammatory or corticosteroids concomitantly with nicorandil increase their risk of gastrointestinal ulceration, perforations and haemorrhage compared with taking either medicine alone. Patients with diverticular disease may be at particular risk of fistula formation or bowel perforation compared to patients without the disease.

Nicorandil is now contraindicated in patients with hypovolaemia and pulmonary oedema and should be used with caution in combination with medicines which increase potassium levels, especially in patients with moderate to severe renal impairment.

The updated SPCs and PILs can be found [here](#).
Non-Medical Prescribers-Starters and Leavers

Monthly queries are raised by the Business Services Authority regarding Non-medical Prescribers not recognised or linked to Practice budget codes.

Please can Practices let the Non-medical Prescribing Lead know when:

- Practices recruit a Non-medical Prescriber to the Practice
- A Non-medical Prescriber successfully completes the prescribing course and become a newly qualified Non-medical Prescribers working in the Practice
- A Non-Medical Prescriber leave the practice
- Where there is a change of circumstance for the Non-Medical Prescriber, such as change of name
- Where a Non-Medical Prescriber may work in more than one practice

A notification of amendment form is completed and this enables the Non-medical Prescriber to be allocated to the correct Practice budget code.

Please email b.baker@nhs.net with any changes

Please click here for NEW Devon Non-Medical Prescribing registration form

Updated Guidance Sheet-Continence Top Tips-North and East

A comprehensive continence assessment is required before considering any continence appliance. Product selection should be made to meet patient needs on an individual basis, as not all products are suitable for all.

Please click here to access Guidance Sheet for Top Tips for the prescribing of Continence products:

ScriptSwitch and Windows 7 and other software or hardware upgrades

For the attention of Practice Managers:
Recently some practices have been moving over to the Windows 7 (W7) operating system. When this change happens one of the consequences is that ScriptSwitch stops working and needs re-installing on all clinical terminals where W7 has been installed.

Practices moving to the W7 operating system should, therefore, contact Optum on the number below if they are having W7 installed to book an engineer to come out and re-install ScriptSwitch as soon as possible following the upgrade.

Practices should also be aware that a change in hardware (e.g. PC towers) or software and/or clinical system will also require the re-installing of ScriptSwitch. Practices should discuss this with Optum on the number below to arrange a suitable practice visit.

Optum customer services: Customer Service Tel: 02476 214 700 or email: support@scriptswitch.com
Formulary News

South and West Continence Chapter-Intermittent Catheter product change

In the South and West Continence chapter, intermittent catheters, B. Braun Medical Actreen Glys Catheter has now been discontinued.

The new product that is now first formulary choice for intermittent catheter is Actreen Hi-Lite Catheter

- Benefits of the catheter
- Ready to use coated with hydrophilic lubricant, no need to add water
- Improved no touch system
- Foldable catheter
- Discreet packaging, compact to fit into a pocket
- No risk of drying out
- No risk of residue

For further information please click here

Temporary shortage of INSUMAN BASAL and INSUMAN COMB 25 insulin human

We have been made aware of a possible supply shortage of the following Sanofi products:

- **Insuman Basal 100IU/mL** – suspension for injection in a cartridge – SC use
- **Insuman Comb 25 100IU/mL** – suspension for injection in a cartridge
- **Insuman Basal Solostar 100IU/mL** – suspension for injection in a pre-filled oen – SC use
- **Insuman Comb 25 Solostar 100IU/mL** – suspension for injection in a pre-filled pen – SC use

The shortage is due to limited capacity at the manufacturing site, not due to any safety issue and Insuman currently on the market can be continue to be used.

Sanofi have given the following guidance in the case of a lack of supply:

Patients should be switched to an alternative suitable human insulin preparation under the supervision of a healthcare professional that can provide training on the new delivery device. Blood levels should be monitored more closely during this period

For Insuman Basal the alternatives would be Humulin I or Insulatard. For Insuman Comb 25 the alternative would be Humulin M3 (please note that this contain a different ration of rapid/basal insulin and dose adjustment may be required).
OUT OF STOCK INFORMATION

We are aware of a number of medications that are currently out of stock. Please see chart below for your information.

<table>
<thead>
<tr>
<th>Product</th>
<th>Generic name</th>
<th>Pack size</th>
<th>When the product is expected to be back in stock</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cyclimorph 10 Injection Ampoules</td>
<td>Cyclizine + Morphine</td>
<td>1ml x 5</td>
<td>We expect the product to be back in stock by mid December 15</td>
</tr>
<tr>
<td>Deltastab Injection 25mg/ml</td>
<td>Prednisolone acetate</td>
<td>1ml x 10</td>
<td>We expect the product to be back in stock by 2nd Quarter 16</td>
</tr>
<tr>
<td>Demeclocycline Hydrochloride 150mg Capsules</td>
<td>Demeclocycline hydrochloride</td>
<td>28</td>
<td>We expect the product to be back in stock by End of January 16</td>
</tr>
<tr>
<td>Deltastab Injection 25mg/ml</td>
<td>Prednisolone acetate</td>
<td>1ml x 10</td>
<td>We expect the product to be back in stock by 2nd Quarter 16</td>
</tr>
<tr>
<td>Erythroped A Tablets</td>
<td>erythromycin ethylsuccinate</td>
<td>28</td>
<td>We expect the product to be back in stock by End of July 16</td>
</tr>
<tr>
<td>Erythroped SF Suspension 125mg/5ml</td>
<td>erythromycin ethylsuccinate</td>
<td>140ml x 20</td>
<td>We expect the product to be back in stock by End of January 16</td>
</tr>
<tr>
<td>Erythroped SF Suspension 250mg/5ml</td>
<td>erythromycin ethylsuccinate</td>
<td>140ml x 20</td>
<td>We expect the product to be back in stock by End of January 16</td>
</tr>
<tr>
<td>Guanethidine monosulphate Ampoules 10mg/ml</td>
<td>Guanethidine monosulphate</td>
<td>1ml x 5</td>
<td>We expect the product to be back in stock by End of January 16</td>
</tr>
<tr>
<td>Haloperidol 5mg/ml solution for injection</td>
<td>Haloperidol</td>
<td>1ml x 10</td>
<td>We expect the product to be back in stock by 4th Quarter 16</td>
</tr>
<tr>
<td>Hydrocortistab injection 25mg/ml</td>
<td>Hydrocortisone acetate</td>
<td>1ml x 10</td>
<td>We expect the product to be back in stock by 2nd Quarter 16</td>
</tr>
<tr>
<td>Metoclopramide Hydrochloride</td>
<td>Metoclopramide Hydrochloride</td>
<td>2ml x 10</td>
<td>We expect the product to be back in stock by 1st Quarter 16</td>
</tr>
<tr>
<td>Prochlorperazine Mesilate 12.5mg/ml solution for injection</td>
<td>Prochlorperazine mesilate</td>
<td>1ml x 10</td>
<td>We expect the product to be back in stock by 4th Quarter 16</td>
</tr>
<tr>
<td>Ropivacaine 10mg/ml solution for injection</td>
<td>Ropivacaine Hydrochloride</td>
<td>10ml x 10</td>
<td>We expect the product to be back in stock by last week of March 16</td>
</tr>
<tr>
<td>Sulfinpyrazone 100 mg Tablets</td>
<td>Sulfinpyrazone</td>
<td>84</td>
<td>We expect the product to be back in stock by 2nd Quarter 16</td>
</tr>
<tr>
<td>Sulfinpyrazone 200mg Tablets</td>
<td>Sulfinpyrazone</td>
<td>84</td>
<td>We expect the product to be back in stock by 2nd Quarter 16</td>
</tr>
<tr>
<td>Traxam Pain Relief 3% w/w Gel</td>
<td>Felbinac</td>
<td>30g</td>
<td>We expect the product to be back in stock by 4th Quarter 16</td>
</tr>
<tr>
<td>Traxam Pain Relief 3% w/w Gel</td>
<td>Felbinac</td>
<td>100g</td>
<td>We expect the product to be back in stock by 4th Quarter 16</td>
</tr>
<tr>
<td>Triamterene 50mg Capsules</td>
<td>Triamterene</td>
<td>30</td>
<td>We expect the product to be back in stock by end of 1st Quarter 16</td>
</tr>
</tbody>
</table>
Medicines Optimisation Governance news

Drug Safety Update November 2015

Crizotinib (Xalkori▼): risk of cardiac failure

There have been reports of severe, sometimes fatal, cases of cardiac failure in patients treated with crizotinib, a medicine licensed for the treatment of non-small cell lung cancer. Healthcare professionals are advised to monitor all patients for signs and symptoms of heart failure (including dyspnoea, oedema, or rapid weight gain from fluid retention) and consider reducing the dose, or interrupting or stopping treatment if symptoms of heart failure occur.

Vemurafenib (Zelboraf▼): risk of potentiation of radiation toxicity

Vemurafenib (Zelboraf▼) is indicated as monotherapy for the treatment of adults with BRAF V600 mutation-positive unresectable or metastatic melanoma. Prescribers should be aware of the risk of potentiation of radiation toxicity with vemurafenib when given before, during, or after radiotherapy.

Please continue to report suspected adverse drug reactions to crizotinib, vemurafenib or any other medicines on a Yellow Card.

For further information please click here.

Useful links

- NICE update bulletin December 2015
- Medicines Optimisation: Information for Healthcare professionals
- Joint Formularies
- Medicines Optimisation Post Live

Please send us your comments, queries and any other feedback to the Medicines Optimisation Team email: d-ccg.medicinesoptimisation@nhs.net

Information within this Newsletter is published on the Medicines Optimisation Post Live. Every effort is made to ensure the accuracy of information contained within this newsletter; for full prescribing information on any of the drugs mentioned please consult the reference source cited, individual Data Sheets, Summary of Product Characteristics and the current edition of the British National Formulary (BNF).